Category: Clinical Trials & Cancer Treatment

Categories
Anti Cancer Cancer Research & Clinical Evidence Cancer Support & Encouragement Cancer Treatment & Clinical Research Cancer Treatment Claims & Critical Analysis Cancer Treatment Research & Critical Analysis Clinical Trials & Cancer Treatment Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Health & Wellness Hulscher Study Ivermectin Joe Tippins Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Wellness Company

The Only Registered Human Ivermectin Oncology Trial (NCT05318469): What Is Actually Known

The Only Registered Human Ivermectin Oncology Trial

Courage Against Cancer emphasizes the importance of distinguishing between the registered trial NCT05318469 and the controversial Hulscher et al. 2026 study. The former aims to assess ivermectin’s safety and efficacy for metastatic triple-negative breast cancer under rigorous oversight, while the latter lacks validated endpoints and ethical scrutiny. Valid results are pending.

Categories
Anti Cancer Breakthrough Therapies Cancer Research & Clinical Evidence Cancer Research Literacy Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treratments Cancer Wellness Protocols Clinical Trials & Cancer Treatment Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Health & Wellness Hulscher Study Ivermectin Joe Tippins Mebendazole Non-Chemo Cancer Treatments Pancreatic Cancer Repurposed Drug Studies Research News & Updates Wellness Company

How Cancer Patients and Caregivers Should Evaluate Viral Claims About Unproven Treatments

Hulscher 2026 Study and how claims can go viral

The article from Courage Against Cancer emphasizes the importance of critically evaluating cancer treatment claims, particularly viral studies like the 2026 Hulscher et al. ivermectin-mebendazole paper. It provides a structured framework for assessing study validity, distinguishing between preclinical and clinical evidence, and understanding potential conflicts of interest to make informed treatment decisions.

Categories
Anti Cancer Cancer Research & Clinical Evidence Cancer Research Literacy Cancer Treatment & Clinical Research Cancer Treatment Claims & Critical Analysis Cancer Treatment Guidance Cancer Treatment Research & Critical Analysis Cancer Wellness Protocols Clinical Trials & Cancer Treatment Colorectal Cancer Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Hulscher Study Integrative Oncology Insights Ivermectin Mebendazole Non-Chemo Cancer Treatments Pancreatic Cancer Repurposed Drug Studies Research News & Updates Wellness Company

NCI Ivermectin Research vs. the Hulscher Study: Two Completely Different Things

NCI and Hulscher Study Critique

Courage Against Cancer clarifies the distinction between the legitimate preclinical research conducted by the NCI on ivermectin and the controversial Hulscher observational study. The latter’s findings are compromised due to bias and conflicts of interest. Conflating the two may mislead patients, potentially exploiting their vulnerability and delaying effective treatments.

Categories
Anti Cancer Breakthrough Therapies Cancer Research & Clinical Evidence Cancer Support & Encouragement Cancer Treatment & Outcomes Cancer Treatment Guidance Cancer Wellness Protocols Clinical Trials & Cancer Treatment Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Fenbendazole Gut-Microiome Health & Wellness Integrative Oncology Insights Ivermectin Joe Tippins Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Wellness Company

What Does an 84.4% ‘Clinical Benefit Rate’ Actually Mean — and What It Doesn’t

84 percent clinical benefit rate

Courage Against Cancer critiques the 2026 study by Hulscher et al., which claims an 84.4% clinical benefit rate from self-reported outcomes about off-label ivermectin and mebendazole in cancer patients. The study lacked control and independent verification, raising concerns over reliability and potential conflicts of interest. Caution is advised before drawing conclusions from such data.

Categories
Anti Cancer Breakthrough Therapies Cancer Treatment & Clinical Research Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treatment Options Cancer Wellness Protocols Clinical Trials & Cancer Treatment Critical Evaluation of Cancer Research drug repurposing Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Health & Wellness Hulscher Study Ivermectin Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Research & Science Research News & Updates Wellness Company

Is Ivermectin approved by the FDA as a cancer treatment for any type of cancer?

Is ivermectin FDA approved for cancer treatment

As of 2026, the FDA has not approved ivermectin for any cancer treatments; it is only sanctioned for specific parasitic infections. While off-label prescribing is legal, there is no solid evidence supporting its efficacy in oncology. Patients should consult their healthcare providers before altering treatment plans based on unverified claims.

Categories
Anti Cancer Cancer Support & Encouragement Cancer Treatment & Clinical Research Cancer Treatment Claims & Critical Analysis Cancer Treatment Options Cancer Wellness Protocols Clinical Trials & Cancer Treatment Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Health & Wellness Hulscher Study Ivermectin Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Research & Science Wellness Company

The Wellness Company Study of Ivermectin and Mebendazole Review

Hulscher cohort study of Ivermectin and Mebendazole

A study conducted by Dr. Nicolas Hulscher at the Wellness Company examined the effects of compounded Ivermectin and Menebedazole on 197 cancer patients over six months. While results appear promising, concerns arise regarding the study’s methodology, raising questions about the necessity of formal clinical trials for FDA consideration.

Categories
Anti Cancer cancer research Cancer Support & Encouragement Cancer Treatment Cancer Treatment & Clinical Research Cancer Treatment Options chemotherapy Clinical Trials & Cancer Treatment FAQ

What factors determine if I’m a candidate for clinical trials?

Clinical trial eligibility is determined by factors such as cancer type, stage, treatment history, overall health, and age. Trials vary in their requirements, and patients are encouraged to consult their medical team for guidance. Resources like ClinicalTrials.gov can assist in exploring available options. Always discuss participation with healthcare providers.

Categories
Anti Cancer cancer research Cancer Support & Encouragement Cancer Treatment Cancer Treatment & Clinical Research Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treatment Guidance Cancer Wellness Protocols chemotherapy Clinical Trials & Cancer Treatment Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Health & Wellness Hulscher Study immunotherapy Ivermectin Mebendazole Non-Chemo Cancer Treatments Research & Science Research News & Updates

What questions should cancer patients ask their oncologist before considering off-label ivermectin based on this study?

The study by Hulscher et al. (2026) raised concerns regarding the use of ivermectin for cancer treatment, being observational and self-reported without rigorous trials. Potential conflicts of interest and unresolved questions about data integrity highlight the need for caution. Patients should discuss these issues with their oncologist and consider ongoing clinical trials.

Categories
Anti Cancer Breakthrough Therapies Cancer Support & Encouragement Cancer Treatment & Clinical Research Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treatment Guidance Cancer Treratments Clinical Trials & Cancer Treatment Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Health & Wellness Hulscher Study Ivermectin Non-Chemo Cancer Treatments preclinical trial Repurposed Drug Studies Research News & Updates Wellness Company

What is clinical trial NCT05318469 and what does it study regarding ivermectin and cancer?

The trial NCT05318469 evaluates ivermectin as an adjunct therapy for metastatic triple-negative breast cancer, adhering to rigorous clinical standards. It contrasts with the controversial 2026 Hulscher et al. study, which raised concerns about methodological integrity. Ivermectin remains unapproved for cancer treatment, emphasizing the need for credible research contexts.

Categories
Anti Cancer Breakthrough Therapies cancer research Cancer Support & Encouragement Cancer Treatment Cancer Treatment & Clinical Research Cancer Treatment & Outcomes Cancer Treatment Claims & Critical Analysis Cancer Treatment Guidance Cancer Treatment Options Cancer Wellness Protocols cancer-prevention chemotherapy Clinical Trials & Cancer Treatment Evaluating Cancer Treatment Claims FAQ Health & Wellness immunotherapy Integrative Oncology Insights Non-Chemo Cancer Treatments

How are newer cancer treatments different from traditional chemotherapy?

Newer cancer treatments, including targeted therapies and immunotherapies, attack cancer cells more precisely than traditional chemotherapy, which affects all rapidly dividing cells. These innovative approaches often result in fewer side effects and improved survival rates for some cancers. Treatment plans may combine old and new methods for optimal outcomes.